Capital World Investors Trims Vertex Pharmaceuticals Stake

Institutional investor reduces holdings in biotech firm by nearly 10%

Mar. 10, 2026 at 11:38am

Got story updates? Submit your updates here. ›

Capital World Investors, a major institutional investor, has reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.8% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The fund now owns 25,910,587 shares of the pharmaceutical company's stock, valued at over $10.1 billion.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases, particularly cystic fibrosis. Changes in ownership by large institutional investors can signal shifts in market sentiment and influence the stock price.

The details

According to the 13F filing, Capital World Investors sold 2,821,556 shares of Vertex Pharmaceuticals during the third quarter. The fund now owns a 10.21% stake in the company, making it the 11th largest holding in its investment portfolio.

  • Capital World Investors reduced its Vertex Pharmaceuticals holdings during the third quarter of 2026.

The players

Capital World Investors

A major institutional investor that manages a diversified portfolio of stocks, including a significant position in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on the discovery, development, and commercialization of therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Capital World Investors' Vertex Pharmaceuticals stake could signal a shift in market sentiment towards the biotech firm, though the reasons behind the move are not entirely clear. Investors will be watching closely to see if other large institutional investors follow suit or if Vertex Pharmaceuticals can continue to attract strong investor support.